'Strong interest from potential partners reinforces our confidence': £1.4m fundraise backs growth ambitions at Northern Ireland biotechnology firm
Fusion Antibodies has conditionally secured the funding following a well-received launch of its OptiMAL platform, with proceeds set to support laboratory investment, global marketing and expansion into key markets such as North America
Belfast-based Fusion Antibodies has conditionally raised £1.4m to accelerate the commercialisation of its OptiMAL platform after its launch was well received.


After launching the platform in December, the listed contract research organisation, which floated in 2017, said it had held positive discussions with potential clients.
The Fusion Antibodies board believes that it is well positioned for significant growth, but "remains cautiously mindful of the potential market volatility and the inherent science-based risks in the work being undertaken by its clients, which can potentially impact the visibility of revenue streams".
The net proceeds of the fundraise, being approximately £1.3m, will be used for the purchase of certain laboratory equipment to enhance the efficiency of the OptiMAL platform, to invest in the company's commercial activities and for general working capital purposes.
The commercial plans will focus on increasing Fusion Antibodies' presence in key geographic markets, such as North America, and promoting OptiMAL through various marketing activities, including at key industry conferences and follow on business development trips.
Adrian Kinkaid, chief executive of Fusion Antibodies, said: "The successful validation and formal launch of our OptiMAL platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time.
"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies.
"This will place the company in a strong position for sustainable growth and help to generate long term value for our shareholders."
Fusion was established in 2001 as a spin out from Queen's University Belfast. It provides a range of services in antibody generation, development, production, characterisation and optimisation.